Hemispherian
Oslo, Oslo, Norway
As the Chief Scientific Officer of Hemispherian, Dr. Adam Robertson, PhD is responsible for all scientific endeavors at the company. Hemispherian private company based in Oslo, Norway that is advancing pharmaceuticals for the treatment of cancers with high unmet needs -- including, glioblastoma, pancreatic and ovarian cancers. Adam has an PhD from the University of North Carolina at Chapel Hill. He then moved to Oslo, Norway where he ran an academic laboratory for 10 years researching DNA base modifications. At the end of his academic career, together with one of his students, Adam discovered the GLIX family of molecules. The GLIX molecules target a mechanism of action specific to all cancers and show great efficacy in treating glioblastoma and other cancers with high unmet needs. Together with one of his students and a colleague from industry, he founded Hemispherian based on the intellectual property developed in Adam's academic laboratory. Hemispherian has been making great progress with Adam as chief scientist. The company's lead asset shows good efficacy, good blood brain barrier penetration, oral bioavailability and is roughly 6 months away from a first in human phase I clinical trial.
